Home 2024
Archives
Engineered endosymbionts as novel cancer therapeutics
Satyajit Hari Kulkarni and Christopher H. Contag from the Institute for Quantitative Health Science and Engineering focus on engineered endosymbionts, which they argue is a paradigm shift in anticancer bacteriotherapy toward killing tumors from the inside out.
Engineered endosymbionts for cellular control
Christopher H. Contag from the Institute for Quantitative Health Science and Engineering (IQ) at Michigan State University discusses the potential of engineered endosymbionts as biologically encoded remote controls for regenerative medicine.
